TIL - Instil Bio, Inc.

QQQ $ 440.18 $ 0.66 (0.15 %)

DIA $ 388.83 $ -0.35 (-0.09 %)

SPY $ 517.12 $ -0.53 (-0.1 %)

TLT $ 90.64 $ -0.21 (-0.23 %)

GLD $ 214.07 $ -0.45 (-0.21 %)

Previous Close

$ 11.54

Open

$ 11.37

Bid

$ 10.90 x 100

Ask

$ 0.00 x 0

Day's Range

$ 11.17 - $ 11.68

52 Week Range

$ 6.07 - $ 14.00

Volume

4,847

Average Volume

Market Cap

75.06M

Beta (5Y Monthly)

$ 4.95

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-21-2024	12-31-2023	10-K
2	11-13-2023	09-30-2023	10-Q
3	08-14-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-31-2023	12-31-2022	10-K
6	11-14-2022	09-30-2022	10-Q
7	08-12-2022	06-30-2022	10-Q
8	05-16-2022	03-31-2022	10-Q
9	03-07-2022	12-31-2021	10-K
10	11-15-2021	09-30-2021	10-Q
11	08-12-2021	06-30-2021	10-Q
12	05-13-2021	03-31-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Jefferies Downgrades Instil Bio to Hold, R...
04/12/2024 13:24:12

Jefferies analyst Kelly Shi downgrades Instil Bio (NASDAQ:TIL) from Buy to Hold and raises the price target from $5 to $11.

HC Wainwright & Co. Reiterates Buy on Inst...
03/25/2024 10:08:35

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.

Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85...
03/21/2024 21:08:00

Instil Bio (NASDAQ:TIL) reported quarterly Adj losses of $(1.26) per share which beat the analyst consensus estimate of $(2.85)...

HC Wainwright & Co. Maintains Buy on Insti...
01/22/2024 11:06:42

HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy, adjusts target to $18 from $2.

Baird Reiterates Outperform on Instil Bio,...
01/19/2024 19:13:36

Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $54 price target.

Baird Maintains Outperform on Instil Bio, ...
01/17/2024 19:34:25

Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $100 to $54.

Instil Bio Says As Result Of Workforce Red...
01/16/2024 22:19:39

-SEC Filing

Instil Bio Enters Agreement With Collabora...
01/16/2024 13:26:53

Instil Bio Partners with Cell Therapy Lead...
01/16/2024 13:05:51

Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused o...

Instil Bio Says 1-for-20 Reverse Stock Spl...
12/05/2023 22:02:17

HC Wainwright & Co. Reiterates Buy on Inst...
11/14/2023 11:27:56

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $2 price target.

UPDATE: Instil Bio Q3 Adj EPS $(0.16) Miss...
11/13/2023 22:49:59

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) b...

Instil Bio Q3 Adj EPS $(0.16) Misses $(0.1...
11/13/2023 22:48:03

Instil Bio (NASDAQ: TIL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) ...

HC Wainwright & Co. Reiterates Buy on Inst...
08/17/2023 10:33:32

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $2 price target.

UPDATE: Instil Bio Q2 Adj $(0.11) Beats $(...
08/14/2023 14:30:57

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by ...

Instil Bio Q2 Adj $(0.11) Beats $(0.16) Es...
08/14/2023 11:27:00

Instil Bio (NASDAQ: TIL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by...

Benzinga's Top Ratings Upgrades, Downgrade...
06/29/2023 15:02:40

HC Wainwright & Co. Initiates Coverage On ...
06/29/2023 10:10:17

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Instil Bio (NASDAQ:TIL) with a Buy rating and announce...

Instil Bio Announces Oral Presentation Of ...
06/26/2023 20:40:03

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and ren...

Truist Securities Reinstates Hold on Insti...
04/05/2023 12:53:07

Truist Securities analyst Asthika Goonewardene reinstates Instil Bio (NASDAQ:TIL) with a Hold and maintains $6 price target.